Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vimta LabsBOM:524394 +3.58%84 Interest Coverage is 104.49 as of Jun. 2026, which is 231% above its 10-year median of 31.56. GuruFocus rates BOM:524394 with a GF Score™ of 84/100 and a GF Value™ of ₹495.16 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 92 Medical Diagnostics & Research companies, Vimta Labs ranks better than 84.78% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Vimta Labs's
Operating Income
for the
three
months ended in Jun. 2026 was ₹248 Mil. Vimta Labs's Interest Expense for the
three
months ended in Jun. 2026 was ₹-2 Mil.
Vimta Labs's interest coverage for the quarter that ended in Jun. 2026 was 104.49.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Vimta Labs Ltd has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for Vimta Labs's Interest Coverage or its related term are showing as below:
BOM:524394'
s Interest Coverage Range Over the Past 10 Years
Min: 4.43 Med: 31.56 Max: 208.8
Current: 90.62
BOM:524394's Interest Coverage is ranked better than 84.78% of 92
companies
in the Medical Diagnostics & Research industry
Industry Median: 9.155
vs BOM:524394: 90.62
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Vimta Labs Interest Coverage Related Terms
Vimta Labs Interest Coverage Historical Data
* Premium members only.
The historical data trend for Vimta Labs's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
BOM:524394 vs TMO, DHR, IDXX: Interest Coverage Comparison
For the Diagnostics & Research subindustry, Vimta Labs's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vimta Labs Interest Coverage vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Vimta Labs's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Vimta Labs's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vimta Labs (BOM:524394) has a Interest Coverage of 104.49 as of Jun. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Vimta Labs and its competitors. This is 231% above median its historical median of 31.56. Over the past decade, Vimta Labs' Interest Coverage has ranged from 4.43 to 208.80. According to the industry distribution chart, Vimta Labs ranks #14 out of 92 companies in the Medical Diagnostics & Research industry, placing it in the top 15.2%.
Is Vimta Labs' Interest Coverage too high?
Vimta Labs' current Interest Coverage of 104.49 is 231% above median its 10-year median of 31.56. Over the past 10 years, this metric has ranged from a low of 4.43 to a high of 208.80. The Medical Diagnostics & Research industry median Interest Coverage is 9.16. Vimta Labs' value of 104.49 is 1041.3% above this industry median. Based on the distribution chart, Vimta Labs ranks #14 out of 92 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Vimta Labs has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vimta Labs' Interest Coverage compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Vimta Labs ranks #14 out of 92 companies for Interest Coverage. This places Vimta Labs in the top 15% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 9.16. Vimta Labs' value of 104.49 is 1041.3% above this benchmark. Historically, Vimta Labs' own Interest Coverage has ranged from 4.43 to 208.80 over the past decade. While the company's 10-year median is 31.56 vs. the industry median of 9.16, Vimta Labs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Medical Diagnostics & Research company?
The median Interest Coverage among Medical Diagnostics & Research companies is 9.16, based on 92 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vimta Labs's current Interest Coverage of 104.49 is 1041.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Vimta Labs and its competitors. For the Medical Diagnostics & Research industry, the median Interest Coverage is 9.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vimta Labs's current Interest Coverage is 104.49, which is 231% above median its own 10-year median of 31.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vimta Labs stock overvalued right now?
Based on GuruFocus' analysis, Vimta Labs (BOM:524394) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹495.16, compared to a current price of ₹641.20 — trading 29.5% above its estimated fair value. The current Interest Coverage is 104.49, which is 231% above median its 10-year median of 31.56 and 1041.3% above the Medical Diagnostics & Research industry median of 9.16. Vimta Labs' overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Vimta Labs (BOM:524394), the current Interest Coverage is 104.49 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vimta Labs (BOM:524394) Overvalued in 2026?
Based on GuruFocus' analysis, Vimta Labs stock appears to be overvalued.
The current stock price of ₹641.20 is trading 29.5% above its estimated GF Value™ of ₹495.16.
GuruFocus considers Vimta Labs to be Modestly Overvalued.
Key valuation signals for BOM:524394:
Interest Coverage: 104.49 (231% above median its 10-year median of 31.56)
GF Value™: ₹495.16 vs. price of ₹641.20 (29.5% above fair value)
Industry Position: 1041.3% above the Medical Diagnostics & Research median (#14 of 92)
No single metric tells the full story. See the BOM:524394 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vimta Labs Ltd is a comprehensive contract research and testing organization, providing a wide range of services to pharmaceutical, biopharmaceutical, food, consumer goods, electronic, electrical, agrochemical, healthcare, medical device, and many other industries. Its services portfolio includes testing and contract research services in the fields of clinical research, pre-clinical research, clinical diagnostics, biopharma services, analytical testing, research and environmental studies, and Others. It has only one reportable segment namely Contract Research and Testing Services which generates the revenue.
84GF Score
Get the complete analysis for BOM:524394
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524394 has been successfully added to your 
